Flexible design and efficient implementation of adaptive dose-finding studies

Journal of Biopharmaceutical Statistics

Volumn 17, Issue 6, 2007, Pages 1033-1050

  Weir, Christopher J ^a   Spiegelhalter, David J ^b   Grieve, Andrew P ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute stroke; Bayesian adaptive design; Markov chain Monte Carlo; Normal dynamic linear model

Indexed keywords

NEUTROPHIL INHIBITORY FACTOR; PLACEBO; UK 279276; UNCLASSIFIED DRUG;

ALGORITHM; CONFERENCE PAPER; DOSE RESPONSE; DRUG RESEARCH; HUMAN; MATHEMATICAL ANALYSIS; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; STROKE;

ACUTE DISEASE; BAYES THEOREM; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LINEAR MODELS; MARKOV CHAINS; MONTE CARLO METHOD; NEUTROPHILS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STROKE;

EID: 36249016380     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400701643947     Document Type: Conference Paper

References (23)

1. Berry, D. A., Mueller, P., Grieve, A. P., Smith, M., Parke, T., Blazek, R., Mitchard, N., Krams, M. (2001). Adaptive Bayesian designs for dose-ranging drug trials. In: Gatsonis, C., Carlin, B., Carriquiry, A., eds. Case Studies in Bayesian Statistics. New York: Springer-Verlag, pp. 99-181.
2. Brockwell, A. E., Kadane, J. B. (2003). A gridding method for sequential analysis problems. Journal of Computational and Graphical Statistics 12:566-584.
3. Christen, J. A., Nakamura, M. (2003). Sequential stopping rules for species accumulation. Journal of Agricultural, Biological, and Environmental Statistics 8:184-195.
4. Dragalin, V. (2006). Adaptive designs: Terminology and classification. Drug Information Journal 40:425-435.
5. Garrett-Mayer, E. (2006). The continual reassessment method for dose-finding studies: A tutorial. Clinical Trials 3:57-71.
6. Gelfand, A. E. (1996). Model determination using sampling-based methods. In: Gilks, W. R., Richardson, S., Spiegelhalter, D. J., eds. Markov Chain Monte Carlo in Practice. London: Chapman and Hall, pp. 145-161.
7. Jorgensen, H. S., Nakayama, H., Raaschou, H. O., Vive-Larsen, J., Stoier, M., Olsen, T. S. (1995). Outcome and time course of recovery in stroke. Part I: Outcome. The Copenhagen stroke study. Archives of Physical Medicine and Rehabilitation 76:399-405.
8. Karrison, T. G., Huo, D., Chappell, R. (2003). A group sequential, response-adaptive design for randomized clinical trials. Controlled Clinical Trials 24:506-522.
9. Krams, M., Lees, K. R., Hacke, W., Grieve, A. P., Orgogozo, J. M., Ford, G. A., for the ASTIN study investigators. (2003). Acute stroke therapy by inhibition of neutrophils (ASTIN): An adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 34:2543-2548.
10. O'Quigley, J., Pepe, M., Fisher, L. (1990). Continual reassessment method: A practical design for Phase I clinical trials in cancer. Biometrics 46:33-48.
11. Robbins, H., Monro, S. (1951). A stochastic approximation method. Annals of Mathematical Statistics 29:400-407.
12. Rosenberger, W. F. (1996). New directions in adaptive designs. Statistical Science 11:137-149.
13. Rosenberger, W. F., Flournoy, N., Durham, S. D. (1997). Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs. Journal of Statistical Planning and Inference 60:69-76.
14. Scandinavian Stroke Study Group. (1985). Multicenter trial of hemodilution in ischemic stroke - background and study protocol. Stroke 16:885-890.
15. Smith, M. K., Jones, I., Morris, M. F., Grieve, A. P., Tan, K. (2006). Implementation of a Bayesian adaptive design in a proof of concept study. Pharmaceutical Statistics 5:39-50.
16. Spiegelhalter, D. J., Freedman, L. S., Parmar, M. K. B. (1994). Bayesian approaches to randomized trials. Journal of the Royal Statistical Society Series A 157:357-416.
17. Spiegelhalter, D. J., Thomas, A., Best, N. G., Lunn, D. (2003). WinBUGS version 1.4 user manual. edition. MRC Biostatistics Unit, Cambridge, available from www.mrcbsu.cam.ac.uk/bugs.
18. Storer, B. E. (1989). Design and analysis of Phase I clinical trials. Biometrics 45:925-937.
19. Stroke Therapy Academic Industry Roundtable (STAIR). (1999). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-2758.
20. Wei, L. J. (1979). The generalized Pólya's urn design for sequential medical trials. Annals of Statistics 7:291-296.
21. Wei, L. J., Durham, S. (1978). The randomized play-the-winner rule in medical trials. Journal of the American Statistical Association 73:840-843.
22. West, M. J., Harrison, P. J. (1997). Bayesian Forecsting and Dynamic Models. 2nd ed. New York: Springer-Verlag.
23. Whitehead, J., Brunier, H. (1995). Bayesian decision procedures for dose determining experiments. Statistics in Medicine 14:885-893.